Adderall and Cardiovascular Effects in Adults with ADHD

Plain-language summary

Research suggests that while ADHD medications, including Adderall, are generally not associated with a heightened risk of cardiovascular disease, there is ongoing discussion and some indication of potential, modest increases in risk for certain acute cardiac events. More research is needed to fully understand these risks, especially in adults.

Key findings

• A comprehensive review of many studies indicates no strong link between ADHD medication use and overall cardiovascular disease risk.
• Although overall risk appears low, there is some suggestion that specific heart problems like cardiac arrest or fast heart rhythms might see a small increase in risk with ADHD medication use, but this is not definitive.
• Past concerns about Adderall and cardiac deaths led to its temporary removal from the market in Canada, but it was reintroduced because it was not possible to definitively prove an increased risk.
• Future research aims to identify specific risk factors that might make some individuals more susceptible to adverse cardiovascular events when taking stimulant medications like Adderall.
• There is emerging interest in understanding if long-term Adderall use could contribute to heart muscle conditions (cardiomyopathy), but this is still being investigated.

Studies cited (6)

1. ADHD medication use not associated with risk of cardiovascular disease — (2023, The Brown University Psychopharmacology Update, systematic-review)

   A systematic review and meta‐analysis comprising 19 studies has found no significant association between use of medications for attention‐deficit hyperactivity disorder (ADHD) and risk of cardiovascular disease. The findings could not rule out the possibility of a modest increase in risk of cardiac arrest or tachyarrhythmias, the investigators reported. Results were published online Nov. 23, 2022, in JAMA Network Open.

2. Acute Cardiovascular Responses to Amphetamine/Dextroamphetamine Salts (Adderall) in Adderall-Naïve Young Adults: A Randomized Clinical Trial — Somers KR, Bock JM, Covassin N (2026, Mayo Clinic proceedings, rct)

   DOI: 10.1016/j.mayocp.2025.12.005

3. Inconclusive evidence puts Adderall back on the market — W. Kondro (2005, Canadian Medical Association Journal, observational)

   Health Canada has reintroduced Adderall (amphetamine salts) to the Canadian market after an independent panel found it impossible to accurately ascertain whether the drug increases the risk of cardiac death. Adderall, a central nervous stimulant used in treating attention-deficit hyperactivity disorder (ADHD), was taken off the market in February after manufacturer Shire Biochem Inc. disclosed 20 sudden deaths and 12 strokes worldwide among patients taking the drug, or its one-a-day formulation Adderall XR (the only version sold in Canada). Shire appealed the Health Canada decision, and

4. Risk Factors for Adverse Cardiac Events in Individuals Prescribed Stimulants Across the Lifespan — Destin Groff, Wen-Jan Tuan, K. Holt (2025, Journal of Attention Disorders, other)

   Introduction: Prescription stimulants are an effective FDA approved treatment for attention deficit hyperactivity disorder (ADHD) however their safety has come under scrutiny. Multiple studies demonstrate safe use in pediatric populations, but prescriptions are increasing to adults and it is not evident which comorbidities might place people at risk of adverse outcomes. The aim of this study is to identify risk factors of adverse cardiovascular events for individuals exposed to stimulants across the lifespan. Methods: We conducted a case control study utilizing the TriNetX research network dat

5. Prolonged Amphetamine-Dextroamphetamine Use: An Unrecognized Cause of Cardiomyopathy — Habeb B, Demirag N, Retzloff J (2025, Cureus, other)

   DOI: 10.7759/cureus.80553 PMCID: PMC11993926

6. Adult ADHD Medications and Their Cardiovascular Implications — Sinha A, Lewis O, Kumar R (2016, Case reports in cardiology, other)

   DOI: 10.1155/2016/2343691 PMCID: PMC4992783